GLP1 receptor agonists like semaglutide and tirzepatide now offer metabolic breakthroughs, approved to reduce appetite, enhance glucose control, and lower body weight in a medically supervised context
People with type 2 diabetes need improved blood sugar control, especially those who could benefit from weight loss or cardiovascular risk reduction
Research suggests that hypoxia (low oxygen levels) may play a role in MS
CONTACT US No products were found matching your selection
Get notified when new sourcing explainers, COA breakdowns, and calculator-linked research guides go live
The injectable segment held the largest market share in 2024, supported by the early introduction and widespread use of injectable formulations such as liraglutide, semaglutide, and tirzepatide